Sandoz enters agreement for proposed trastuzumab biosimilar
HOLZKIRCHEN, Germany – Sandoz, a Novartis division and a global leader in biosimilars, announced Tuesday that it has entered into an agreement to commercialize a proposed trastuzumab biosimilar.